Tenax Therapeutics, Inc.
TENXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeTenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. The company carries a $420.4M market cap, placing it firmly in the small-cap category. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Market Cap
$420.4M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-11.50
EPS (TTM)
$-1.41
EPS (Fwd)
$-1.38
ROE
-51.7%
ROA
-32.7%
Cash
$118.8M
Total Debt
$0
Free CF
-$18.7M
52W Change
165.9%
Annual Financials
Cash vs Debt
Tenax Therapeutics, Inc. reports $118.8M in cash and $0 in total debt. Free cash flow is running at -$18.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -51.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tenax Therapeutics, Inc. and its sector.